10-Q: Owens & Minor Reports Q2 Loss Amid Divestiture, Deal Breakup

Owens & Minor, Inc. reported a significant net loss in Q2 2025, primarily driven by the classification of its P&HS segment as discontinued operations and the termination of the Rotech acquisition.

Summary

• Net revenue from continuing operations increased by 3.3% to $681.9 million for the three months ended June 30, 2025, and by 4.4% to $1.36 billion for the six months ended June 30, 2025.
• The company reported a net loss of $869.1 million for Q2 2025, a substantial increase from a $31.9 million net loss in Q2 2024.
• Loss from discontinued operations, net of tax, was $785.2 million for Q2 2025 and $806.4 million for the six months ended June 30, 2025.
• A goodwill impairment charge of $106.4 million and a loss of $649.1 million on classification to held for sale were recognized in connection with the P&HS segment.
• The acquisition of Rotech Healthcare Holdings Inc. was mutually terminated on June 3, 2025, resulting in an $80.0 million transaction breakage fee and $18.3 million in transaction financing fees.
• A commercial payor notified the company of its intent to terminate contracts representing approximately 12% ($160 million) of net revenue for the six months ended June 30, 2025, and nearly all capitation revenue.
• Adjusted EBITDA (non-GAAP) from continuing operations increased to $96.6 million for Q2 2025 (from $91.1 million in Q2 2024) and to $192.7 million for the six months ended June 30, 2025 (from $160.3 million in Q2 2024).
• The company initiated a $100 million share repurchase program on February 26, 2025, repurchasing approximately 0.8 million shares for $6.6 million year-to-date.
• Total equity shifted to a deficit of $281.0 million at June 30, 2025, compared to $586.4 million at December 31, 2024.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the massive net loss driven by discontinued operations, significant impairment charges, and the substantial costs associated with the terminated Rotech acquisition. The loss of a major commercial contract and adverse CMS determination also contribute to a challenging outlook, despite some revenue growth in continuing operations and increased Adjusted EBITDA.

Positives

• Net revenue from continuing operations increased by 3.3% for the quarter and 4.4% year-to-date, driven by sales growth in several product categories.
• Sales growth was notable in sleep therapy (+6.7% Q2), ostomy (+10.3% Q2), and urology (+11.9% Q2).
• Improved collection rates contributed to revenue growth in continuing operations.
• Selling, general and administrative (SG&A) expenses decreased due to operating efficiencies in revenue cycle and information technology, along with lower benefit costs.
• Adjusted EBITDA (non-GAAP) increased by 6.1% for the quarter and 20.2% year-to-date, indicating improved operational performance excluding one-time charges.
• The company was in compliance with all debt covenants as of June 30, 2025.
• A $100 million share repurchase program was authorized, with $6.6 million in repurchases completed year-to-date.

Negatives

• Reported a significant net loss of $869.1 million for the three months ended June 30, 2025, compared to a net loss of $31.9 million in the prior year period.
• Incurred a substantial loss from discontinued operations of $785.2 million for the quarter, primarily due to the P&HS segment classification.
• Recognized a goodwill impairment charge of $106.4 million related to the P&HS segment.
• Recorded a loss of $649.1 million on the classification of P&HS assets and liabilities as held for sale.
• Paid an $80.0 million transaction breakage fee due to the termination of the Rotech acquisition.
• Incurred $18.3 million in transaction financing fees related to the terminated Rotech acquisition.
• A commercial payor intends to terminate contracts representing approximately 12% of net revenue and nearly all capitation revenue for the six months ended June 30, 2025.
• Diabetes revenue growth was hindered by market shifts to the pharmacy channel and supplier disruptions.
• A recent CMS determination may reduce reimbursement qualification for non-invasive ventilation products, potentially impacting future revenue.
• Cash provided by operating activities significantly decreased to $2.5 million for the six months ended June 30, 2025, from $63.2 million in the prior year period.
• Total equity shifted from a positive balance of $586.4 million at December 31, 2024, to a deficit of $281.0 million at June 30, 2025.

Risks

• Ability to successfully complete the contemplated sale of the Products & Healthcare Services (P&HS) segment.
• Negative impacts on business, financial results, and operations if the P&HS sale is delayed or not completed, or if the company becomes smaller and less diversified.
• Failure to achieve the full strategic and financial benefits expected from the P&HS segment sale, such as debt repayment and increased focus on Patient Direct segment.
• Incurrence of significant additional costs and expenses related to the P&HS sale process, including division costs.
• Disruptions and uncertainty surrounding the P&HS sale process could affect relationships with customers, suppliers, and teammates, potentially impacting retention.
• Requirement to provide transitional services to a buyer post-P&HS sale, which may divert management attention and not fully compensate costs.
• Need to transfer or replace certain shared contracts in connection with the P&HS sale, potentially leading to less favorable terms or increased expenses.
• Retained liabilities from divested businesses or sold assets could adversely affect financial results.
• Potential dilutive impact to future earnings if the loss of revenue and profits from divestiture is not offset.
• Significant write-offs, including goodwill and other intangible assets, could materially adversely affect results of operations or financial condition.
• Increasing competitive and pricing pressures in the marketplace.
• Dependence on retaining existing and attracting new customers, and reliance on sales to certain key customers.
• Dependence on certain vendors, suppliers, and third-parties for key components, raw materials, finished goods, equipment, and services.
• Ability to successfully identify, close, manage, or integrate acquisitions.
• Ability to successfully implement strategic initiatives.
• Ability to successfully manage international operations, including risks associated with changes in international trade regulations, foreign currency volatility, and adverse tax consequences.
• Uncertainties related to the impacts of current and potential tariffs and other trade-related measures, restrictions, and policies.
• Uncertainties related to, and ability to adapt to and comply with, changes in government regulations, including healthcare, tax, and product licensing laws.
• Risks arising from possible violations of legal, regulatory, or licensing requirements.
• Uncertainties related to general economic, regulatory, and business conditions and ability to adapt to changes in product pricing and other terms of purchase by suppliers.
• Reduced reimbursement qualification for non-invasive ventilation products due to a recent CMS determination.
• Ability to meet the terms to qualify for supplier funding programs.
• Ability of customers and suppliers to meet financial commitments.
• Changes in manufacturer preferences between direct sales and wholesale distribution.
• Changing trends in customer profiles and ordering patterns.
• Ability to manage operating expenses and improve operational efficiencies.
• Availability of, and ability to access, special inventory buying opportunities.
• Ability to continue to obtain financing at reasonable rates and to manage financing costs and interest rate risk, and ability to refinance, extend, or repay substantial indebtedness.
• Ability to attract and retain talented and qualified teammates.
• Recalls of any products, or safety risks or the discovery of serious safety issues with products.
• Changes, delays, and uncertainties in the reimbursement process.
• Ability to adequately establish, maintain, protect, and enforce intellectual property and proprietary rights, and avoid infringement of third-party rights.
• Ability to engage in transactions that may be limited by restrictive covenants in credit facilities and existing notes.
• Risk of information systems interruption, damage, failure, or data security breach.
• Risks related to public health crises or future outbreaks of health crises.
• Risk of an impairment to goodwill or other long-lived assets.
• Ability to timely or adequately respond to technological advances.
• Failure to adequately insure against losses, including from substantial claims and litigation.
• Ability to meet performance targets specified by customer contracts.
• Capitation arrangements may prove unprofitable if actual utilization rates exceed assumptions.
• Outcome of outstanding and any future litigation, including product and professional liability claims.
• Volatility in the price of common stock and securities.

Future Outlook

The company expects net neutral impacts to financial results through the end of 2025 from the terminated commercial payor contracts, with transitions expected to start late in the fourth quarter of 2025 and continue throughout the first half of 2026. Material future costs related to exit and realignment actions are anticipated. Management believes that cash generated by operating activities, available financing sources, borrowings under the Revolving Credit Agreement, cash on hand, and planned proceeds from the P&HS segment sale will be sufficient to fund working capital needs, capital expenditures, strategic growth, debt payments, and share repurchases. The Receivables Sale Program is not expected to continue in its existing form after the P&HS segment sale. The company is currently assessing the impact of the recently passed OBBB bill on corporate taxation.

Management Comments

• We are actively engaged in discussions regarding the contemplated sale of our P&HS segment. We are in the final stages of our process for the divestiture and have concluded the P&HS segment has met the accounting requirements to be classified as discontinued operations and held for sale as of June 30, 2025. During this process we remain committed to serving our P&HS segment customers.
• Our financial results for the three months ended June 30, 2025 as compared to the prior year were impacted by the transaction breakage fee of $80 million, transaction financing fees, net of $18 million, and an increase in acquisition-related costs of $2.7 million partially offset by a decrease in intangible amortization of $2.5 million due to certain intangible assets that were fully amortized in 2024 and an increase in net revenue.
• A commercial Payor, with which we have multiple separately managed contracts, recently notified us that it intends to terminate certain of our contracts with them. As a result of this notice of termination, we expect net neutral impacts to our financial results through the end of 2025, as the transitions of agreements and services are expected to start late in the fourth quarter of 2025.
• While such transitions of agreements and services are expected to continue throughout the first half of 2026, the specific timing of when these agreements will wind down is highly dependent on the Payors successor providers ability to successfully transition customers among other factors.
• Absent this headwind [diabetes market shifts and supplier disruptions], our revenue growth rate for the three months ended June 30, 2025 would have been approximately 4% as compared to the comparable prior period.
• We believe cash generated by operating activities, available financing sources, and borrowings under the Revolving Credit Agreement, cash on hand, and planned proceeds from a sale of our P&HS segment, will be sufficient to fund our working capital needs, capital expenditures, long-term strategic growth, payments under long-term debt and lease arrangements, debt repurchases, share repurchases and other cash requirements.

Industry Context

Owens & Minor operates as a leading provider of integrated equipment, supplies, and related services for home-based care in the United States. The company is navigating market shifts in the diabetes business, with a trend towards the pharmacy channel impacting its revenue growth. Additionally, a recent determination by the Centers for Medicare and Medicaid Services (CMS) regarding reimbursement qualification for non-invasive ventilation products could make it more challenging for new COPD patients to qualify for coverage, potentially affecting the company's business. The planned divestiture of the P&HS segment will result in a smaller, less diversified company focused solely on the Patient Direct segment, which could increase its vulnerability to changing market conditions and volatility in its financial results.

Legal Proceedings

• No material developments in legal proceedings reported, other than the termination of the Rotech Merger Agreement and the associated $80 million payment.

Stakeholder Impact

• Shareholders face a significant net loss and a shift to an equity deficit, potentially impacting share price and future returns, though a share repurchase program is active.
• Customers of the P&HS segment are assured continued service during the divestiture process, but customers affected by the commercial payor contract termination may experience service transitions.
• Employees ('teammates') may face uncertainty and potential retention challenges due to the P&HS segment sale and ongoing exit/realignment activities.
• Suppliers may see changes in business relationships, particularly those tied to the P&HS segment, and the company's dependence on certain suppliers remains a risk.
• Creditors are impacted by the company's increased current debt maturities, though management asserts compliance with debt covenants and plans to use P&HS sale proceeds for debt repayment.

Next Steps

• Complete the contemplated sale of the Products & Healthcare Services (P&HS) segment.
• Manage the transition of agreements and services for the terminated commercial payor contracts, expected to start late Q4 2025 and continue through H1 2026.
• Incur and manage material future costs related to ongoing exit and realignment actions.
• Assess the full impact of the U.S. Congress's 'One Big Beautiful Bill' (OBBB) on corporate taxation.
• Evaluate market conditions and financing alternatives to optimize the capital structure.
• Potentially repay, repurchase, or redeem outstanding indebtedness.
• Continue share repurchases under the authorized $100 million program.
• Implement new accounting pronouncements (ASU 2023-09 and ASU 2024-03) for future disclosures.

Key Dates

Recommendation

The company reported a staggering net loss of $869.1 million, primarily due to a $785.2 million loss from discontinued operations, which includes a $106.4 million goodwill impairment and a $649.1 million loss on classification of assets held for sale. The termination of the Rotech acquisition incurred an $80 million breakage fee and $18.3 million in financing costs. Furthermore, the loss of a commercial payor contract representing 12% of net revenue and nearly all capitation revenue presents a significant future headwind. The balance sheet has deteriorated, with total equity shifting to a deficit of $281.0 million. While Adjusted EBITDA from continuing operations showed growth, the magnitude of the one-time charges and the ongoing strategic challenges, including the P&HS divestiture and CMS reimbursement changes, indicate severe financial distress and high uncertainty. These factors collectively point to a highly unfavorable investment outlook.

Keywords

Owens & Minor, OMI, Healthcare, Medical Supplies, Patient Direct, Discontinued Operations, Divestiture, P&HS Segment, Rotech Acquisition, Termination Fee, Goodwill Impairment, Contract Termination, CMS, Reimbursement, Debt, Share Repurchase, Quarterly Report